Literature DB >> 9928023

VIP and breast cancer.

T W Moody1, J Leyton, I Gozes, L Lang, W C Eckelman.   

Abstract

VIP1 receptors are present in breast cancer cells. VIP elevates the cAMP and stimulates nuclear oncogene expression in MCF-7 cells. VIPhybrid is a VIP receptor antagonist that inhibits breast cancer proliferation. A VIP analog has been developed for imaging breast tumors. Therefore VIP1 receptors may be utilized for the early detection and treatment of breast cancer.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9928023     DOI： 10.1111/j.1749-6632.1998.tb11189.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  4 in total

1.  Changes in PACAP immunoreactivity in human milk and presence of PAC1 receptor in mammary gland during lactation.

Authors:  Katalin Csanaky; Eszter Banki; Krisztina Szabadfi; Dora Reglodi; Ibolya Tarcai; Levente Czegledi; Zsuzsanna Helyes; Tibor Ertl; Judit Gyarmati; Zalan Szanto; Istvan Zapf; Erika Sipos; Seiji Shioda; Andrea Tamas
Journal:  J Mol Neurosci       Date:  2012-04-27       Impact factor: 3.444

2.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

3.  Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy.

Authors:  Milena Veljkovic; Violeta Dopsaj; Milivoj Dopsaj; Donald R Branch; Nevena Veljkovic; Maria M Sakarellos-Daitsiotis; Veljko Veljkovic; Sanja Glisic; Alfonso Colombatti
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

4.  VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.

Authors:  Terry W Moody; James Dudek; Halina Zakowicz; James Walters; Robert T Jensen; Emmanual Petricoin; Chris Couldrey; Jeff E Green
Journal:  Life Sci       Date:  2004-01-30       Impact factor: 5.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.